Skip to main content
OpenTrials
Completed

NCT Number: NCT00159614

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment

The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

San Diego, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Stable congestive heart failure
  • Impaired renal function
  • Taking oral loop diuretic

Exclusion criteria

  • Acutely decompensated (unstable) and end stage heart failure
  • Diuretics other than loop diuretics
  • Pregnant or nursing
  • Inability to follow instructions
  • Participation in another clinical trial within past 30 days

Treatment and study plan

KW-3902IV

Drug

Primary outcomes

  1. Comparison of KW-3902IV alone or with loop diuretic on renal function.

Sponsors and collaborators

Lead sponsor

NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Industry

Collaborators

  • Merck Sharp & Dohme LLC

Registry information

Official study title

Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With Congestive Heart Failure (CHF) and Renal Impairment

Important dates

Study start
2005
First posted
Sep 12, 2005
Registry last updated
Jan 29, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.